Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Cohort Study
70%
Disease
38%
Survival Rate
32%
Colorectal Cancer
31%
Biological Marker
30%
Immunotherapy
27%
Rivaroxaban
22%
Venous Thromboembolism
22%
Nephrolithiasis
22%
Pancreas Cancer
22%
Mucocutaneous Lymph Node Syndrome
22%
Non-Steroidal Anti-Inflammatory Drug
22%
Cancer Pain
22%
Medication Error
22%
Metastatic Breast Cancer
22%
Programmed Death 1 Receptor
22%
Case-Control Study
22%
Prevalence
22%
Eribulin
22%
Hexachlorocyclohexane
22%
Age Related Macular Degeneration
22%
Gallstone
22%
Capecitabine
22%
Scabies
22%
Anaplastic Lymphoma Kinase Inhibitor
22%
Clinical Trial
16%
Bleeding
12%
Sarcoptes Scabiei
11%
Muscle Cramp
11%
Pancytopenia
11%
Infection
11%
Adverse Event
11%
Disease Predisposition
11%
Paresthesia
11%
Hemodialysis
11%
Dermatitis
11%
Aplastic Anemia
11%
Anticarcinogen
11%
Overall Survival
9%
Breast Cancer
9%
Liver Cancer
9%
Lung Cancer
9%
Anaplastic Lymphoma Kinase
8%
Chemotherapy
7%
Cytotoxic T Lymphocyte Antigen 4
7%
Opiate
7%
Acetylsalicylic Acid
6%
Recurrent Disease
6%
Maintenance Dose
6%
Medicine and Dentistry
Malignant Neoplasm
47%
Cancer Immunotherapy
45%
Signal Transduction
45%
Biological Marker
30%
Case-Control Study
22%
Nonsteroid Antiinflammatory Agent
22%
Kawasaki Disease
22%
Pervasive Developmental Disorder
22%
Biomedical Discipline
22%
Osteoporosis
22%
Programmed Death 1 Receptor
22%
Kidney Stone
22%
Cancer Pain Management
22%
4 Iodo 2,5 Dimethoxyamphetamine
22%
Colorectal Cancer
22%
Oncology
22%
Health Care Cost
22%
Cohort Effect
22%
Disseminated Herpes Zoster
22%
Hexachlorocyclohexane
22%
Analgesia
22%
Epileptic Seizure
22%
ALK Inhibitor
22%
Cohort Analysis
18%
Liver Cirrhosis
15%
Clinical Trial
15%
Programmed Death-Ligand 1
15%
Anticarcinogen
13%
Immunotherapy
13%
Breast Cancer
11%
Lung Cancer
11%
Liver Cancer
11%
Drug Therapy
11%
Hazard Ratio
10%
Scabies
9%
Survival Rate
8%
Proportional Hazards Model
8%
Anaplastic Lymphoma Kinase
8%
Cancer Therapy
7%
CTLA-4
7%
Radiation Therapy
7%
Opiate
7%
Acetylsalicylic Acid
6%
ICD-9-CM
5%
Disease Epidemiology
5%
Targeted Therapy
5%
Patient with Kawasaki Disease
5%
Chemotherapeutic Agent
5%
Drug Use
5%
Nursing and Health Professions
Drug Therapy
51%
Survival Rate
25%
Pilot Study
22%
Elderly (Age Groups)
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
22%
Nursing Home
22%
Medication Therapy Management
22%
Nephrolithiasis
22%
Disease
22%
Capecitabine
22%
Non Small Cell Lung Cancer
22%
Health Care Cost
22%
Metastatic Breast Cancer
22%
Eribulin
22%
Cohort Analysis
17%
Confidence Interval
14%
Ambulatory Care
11%
Independent Practice Association
11%
Malignant Neoplasm
11%
Overall Survival
9%
Medication Error
7%
Health Care Personnel
7%
